另据国发股份2024年年报中的工作部署，公司今年将重点投入滴眼液的品牌营销。目前，国发股份拥有 明星产品"海宝"牌珍珠明目滴眼液，是国家重点技术创新项目，曾获广西及北海科技进步奖，已被纳入 医保与国家基本用药目录。 8月1日，国发股份（600538）披露公告，公司召开第十一届董事会第十七次会议、第十一届监事会第十 次会议，均全票同意聘请上会会计师事务作为公司2025年度以简易程序向特定对象发行A股股票的专项 审计机构。此前，国发股份股东大会已决议授权公司董事会以简易程序向特定对象发行股票，融资总额 不超过3亿元。 国发股份是一家深耕大健康领域，业务覆盖医药制造及医药流通、司法IVD(体外诊断)等领域的企业。 近一年来，国发股份组建了具有国际化视野和技术专长的多元化高管团队，聘请曾在多家国际会计师事 务所任职的姜烨担任董事长，还任命了拥有清华大学技术背景、曾创建电商平台"买卖宝"的张小玮作为 总裁。 核心高管全面履新后，国发股份在推进新发展战略上动作频频。公司表示，IVD行业正经历从"单一检 测"向"精准化、全周期管理"转型，具备核心技术突破能力、全球化布局视野、产业链整合优势的企业 将更具竞争力。作为国发股份 ...

Group 1 - Guofa Co., Ltd. (国发股份) expects a net loss of approximately 5.2 million yuan in the first half of 2025, a significant reduction compared to the same period last year [1] - The company has undergone a complete change in its core management team and is actively promoting a new development strategy focused on technological integration and industry expansion [1][2] - In Q1 2025, Guofa Co., Ltd. achieved operating revenue of 78.61 million yuan and a net profit attributable to shareholders of 3.14 million yuan, marking a turnaround from losses [1] Group 2 - Guofa Co., Ltd.'s main business includes pharmaceutical distribution, in vitro diagnostics (IVD), and pharmaceutical manufacturing, with a focus on optimizing its business structure and leveraging high-tech development [2] - The company has appointed Zhang Xiaowei, who has a strong technical background, as president, indicating a potential shift in business expansion strategies [2] - Guofa Co., Ltd. is focusing on the IVD sector, primarily serving the public security system, and has developed an automated DNA extraction workstation through its subsidiary, Gaosheng Bio [2] Group 3 - The IVD industry is transitioning from "single testing" to "precision and full-cycle management," with companies that have core technological breakthroughs and global integration advantages becoming more competitive [3] - Guofa Co., Ltd. plans to invest in brand marketing for its eye drops, leveraging its geographical advantage in Beihai, known as the "Pearl Capital of China" [3] - The company's "Haibao" brand eye drops, made from high-quality pearls, are a key technological innovation project and have been included in the national medical insurance and essential drug lists [3]

Core Viewpoint - The company held a performance briefing for the fiscal year 2024 and the first quarter of 2025, discussing its business transformation plans and financial performance [1][2]. Group 1: Meeting Details - The performance briefing took place on May 13, 2025, from 11:00 to 12:00 via the Shanghai Stock Exchange Roadshow Center [1]. - Key attendees included the Chairman, CEO, CFO, and independent directors, who engaged with investors through an interactive online format [1]. Group 2: Business Transformation and Progress - The company is focusing on deepening its industrial layout and enhancing market competitiveness, particularly in the judicial IVD sector, with plans for independent R&D and market penetration of DNA testing products [2]. - In the pharmaceutical distribution sector, the company aims to optimize hospital channel management and expand its chain franchise business [2]. - The pharmaceutical manufacturing segment will enhance operational efficiency through organizational restructuring and brand building, with a focus on core products like eye drops [2]. Group 3: Revenue Structure and Performance - The company reported a total revenue of 78.61 million for Q1 2025, with a net profit of 3.14 million, marking a turnaround from losses [9]. - The revenue contributions from different business segments for 2024 were as follows: - Pharmaceutical distribution: 182 million, down 9.34% year-on-year - Judicial IVD: 119 million, up 1.6% year-on-year - Pharmaceutical manufacturing: 35.45 million, down 20% year-on-year [5][6]. Group 4: Future Growth and Market Strategy - The company plans to continue optimizing its business structure, focusing on high-tech development and core biotechnology [8]. - Future growth will be driven by expanding into the health and judicial IVD sectors, leveraging both internal and external growth strategies [10]. - The company is also addressing potential impacts from the US-China trade war by seeking non-US suppliers and promoting domestic product alternatives [12].